Nautilus Biotechnology (NAUT) Q3 2026 Earnings Call: Voyager Launch Roadmap and Cash Runway
Source Tradingkey
Key Takeaways
- Nautilus Biotechnology reported Q3 2026 revenue of $0.2 million from Early Access services and grant funding, reflecting its early commercial stage ahead of the Voyager platform launch.
- Net loss widened to $15.6 million, or $0.12 per share, from $13.6 million, or $0.11 per share, a year earlier. Operating expenses increased 10% to $16.9 million.
- Cash, cash equivalents and investments ended the quarter at $114.3 million. Management expects the current financial plan to provide a cash runway into Q1 2028.
- The company now expects total 2026 revenue to exceed its previous outlook of approximately $0.5 million. Q4 revenue is expected to grow sequentially even without contributions from the ARPA-H-funded SEEDS program.
- Nautilus plans to open Voyager platform preorders in early 2027 and begin instrument shipments in mid-2027. Tau, AKT1 and a second oncology assay are expected to be generally available alongside shipments.
- The company remains focused on developing 20 proteoform assays by mid-2028. It may raise additional capital between now and mid-2027 to expand its assay portfolio, platform capabilities and commercial team.
Core Financial Data
| Metric | Q3 2026 | Comparison / Commentary |
|---|---|---|
| Revenue | $0.2 million | Early Access service revenue and Michael J. Fox Foundation grant revenue |
| Operating expenses | $16.9 million | Up approximately 10% from $15.5 million in Q3 2025 |
| R&D expenses | $10.2 million | Up approximately 6% from $9.6 million, mainly due to personnel, laboratory and professional services costs |
| SG&A expenses | $6.8 million | Up approximately 15% from $5.9 million, driven by legal, marketing and personnel costs |
| Net loss | $15.6 million | Compared with $13.6 million in Q3 2025 |
| Net loss per share | $0.12 | Compared with $0.11 in Q3 2025 |
| Cash, cash equivalents and investments | $114.3 million | Down from $129.2 million at the end of Q2 2026 |
| Quarterly cash use | Approximately $14.9 million | Reflected investments in assay development and launch preparation |
Business and Operating Performance
Disclaimer: For information purposes only. Past performance is not indicative of future results.
Recommended Articles
The Fed will sit still on October 28 — but 100 of 100 economists now expect a December hikeA Reuters poll run October 16-20 found 94 of 100 economists expecting the Fed to hold at 3.75-4.00% on October 28 — and all 100 expecting a hike in December, against less than half a month earlier. The market is close to the same price, with CME FedWatch at roughly 17% for October and 82.8% for December. With the Fed in blackout since October 17, here are the five dates that decide the rest of the year, what each one is priced for, and the two directions each can take.
A Reuters poll run October 16-20 found 94 of 100 economists expecting the Fed to hold at 3.75-4.00% on October 28 — and all 100 expecting a hike in December, against less than half a month earlier. The market is close to the same price, with CME FedWatch at roughly 17% for October and 82.8% for December. With the Fed in blackout since October 17, here are the five dates that decide the rest of the year, what each one is priced for, and the two directions each can take.
Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for October 26, 2026. Read on for the details.
Big Tech's $800 billion AI bill faces its first real test — free cash flow is the judgeAlphabet and Microsoft report after the close on October 28, Amazon on October 29, with hyperscaler AI capex running near $800 billion a year. Meta's negative free cash flow and 9.40% drop on October 22 was the warning; this week's prints decide whether cloud growth and backlog can pay for the buildout. Here are the consensus numbers, the free-cash-flow table and the two-sided test.
Alphabet and Microsoft report after the close on October 28, Amazon on October 29, with hyperscaler AI capex running near $800 billion a year. Meta's negative free cash flow and 9.40% drop on October 22 was the warning; this week's prints decide whether cloud growth and backlog can pay for the buildout. Here are the consensus numbers, the free-cash-flow table and the two-sided test.
Tesla jumps 5% as Barclays puts a $450 target on the SpaceX merger — the chart was already pointing to 431Tesla closed at $391.62 on October 26, up 5.21%, after Barclays upgraded the stock to Overweight and lifted its target to $450 from $370, citing a sharp inflection in Robotaxi miles and a potential SpaceX merger. The move also completed a double bottom at $345.88 and $349.33, with a neckline at $388.56 and a measured target of $431.24. Here is what the upgrade actually says, why the chart and the analyst now point the same way, and what would break the target.
Tesla closed at $391.62 on October 26, up 5.21%, after Barclays upgraded the stock to Overweight and lifted its target to $450 from $370, citing a sharp inflection in Robotaxi miles and a potential SpaceX merger. The move also completed a double bottom at $345.88 and $349.33, with a neckline at $388.56 and a measured target of $431.24. Here is what the upgrade actually says, why the chart and the analyst now point the same way, and what would break the target.
Fed October Rate Decision Preview: Rate Hike Pause Has Become Consensus, How Will US Stocks, Dollar, and Gold React?The Federal Reserve will announce its October interest rate decision at 14:00 Eastern Time on October 28, and Fed Chair Warsh will hold a press conference at 14:30. Markets currently wide
The Federal Reserve will announce its October interest rate decision at 14:00 Eastern Time on October 28, and Fed Chair Warsh will hold a press conference at 14:30. Markets currently wide
